跳至主要内容
临床试验/jRCT2051220042
jRCT2051220042进行中(未招募)不适用

A Single-Center, Randomised, Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide therapy in the patients with severe right heart failure due to pulmonary hypertension

未提供0 个研究点目标入组 30 人开始时间: 2022年11月2日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
30
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
18age old over 至 No limit(—)
性别
All

入选标准

  • Patients who are at least 18 years of age at the time consent is obtained
  • Patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)
  • Patients who meet all of the following criteria for right heart catheterization
  • Mean pulmonary artery pressure greater than 25 mmHg
  • Pulmonary capillary wedge pressure or left ventricular end-diastolic pressure less than 15 mmHg
  • Pulmonary vascular resistance greater than 3 Wood units
  • WHO-FC III or higher
  • Patients with fluid retention (fluid retention on physical examination or echocardiographic evidence of congestion), low cardiac output (cardiac coefficient less than 2.5 L/min/m2 ), or in need of inotropic drugs
  • Patients with written consent from the patient

排除标准

  • Patients with cardiac disease (Eisenmenger's syndrome) who are completely dependent on a right-left shunt for life support
  • Patients with PAH who are eligible for Calcium channel blockers
  • Patients with pulmonary veno-occlusive disease
  • Patients with pulmonary capillary haemangiomatosis
  • Patients with pulmonary hypertension due to left heart disease
  • Patients with pulmonary hypertension due to pulmonary disease and/or hypoxia
  • Patients with pulmonary hypertension with un clear and/or multifactorial mechanisms
  • Patients with a history of hypersensitivity to the investigational drug
  • Pregnant or lactating women, or patients who cannot consent to contraception during the study
  • Patients who plan to participate in other clinical trials or interventional studies during the period of this study
  • Patients who are judged by the investigator or subinvestigator to be inappropriate to participate in this clinical trial for other reasons.

结局指标

主要结局

-

Efficacy: Change in Pulmonary vascular resistance (PVR) at 30 minutes after inhalation of study drug

次要结局

  • Catheter findings(Change from screening time point to each time point (Day 1, Day 2, Day 3))
  • SF36(Change to each time point (Day 3, Day 7, Day 8))

研究者

发起方
未提供

相似试验